Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.

Kristiansen I, Stephan C, Jung K, Dietel M, Rieger A, Tolkach Y, Kristiansen G.

Int J Mol Sci. 2017 May 29;18(6). pii: E1151. doi: 10.3390/ijms18061151.

2.

Is There a Role for Genetic Information in Risk Assessment and Decision Making in Prostate Cancer?

Nowroozi M, Ayati M, Amini E, Mahdian R, Yousefi B, Arbab A, Jamali Zawarei M, Niroomand H, Ghorbani H, Ghadian A.

Nephrourol Mon. 2016 Oct 23;8(6):e41505. eCollection 2016 Nov.

3.

4C-seq revealed long-range interactions of a functional enhancer at the 8q24 prostate cancer risk locus.

Cai M, Kim S, Wang K, Farnham PJ, Coetzee GA, Lu W.

Sci Rep. 2016 Mar 3;6:22462. doi: 10.1038/srep22462.

4.

Concurrent Down-Regulation of PTEN and NKX3.1 Expression in Iranian Patients with Prostate Cancer.

Nodouzi V, Nowroozi M, Hashemi M, Javadi G, Mahdian R.

Int Braz J Urol. 2015 Sep-Oct;41(5):898-905. doi: 10.1590/S1677-5538.IBJU.2014.0036.

5.

High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer.

Barreiro-Alonso A, Lamas-Maceiras M, Rodríguez-Belmonte E, Vizoso-Vázquez Á, Quindós M, Cerdán ME.

Oxid Med Cell Longev. 2016;2016:5845061. doi: 10.1155/2016/5845061. Epub 2015 Nov 23. Review.

6.

Ligand-dependent enhancer activation regulated by topoisomerase-I activity.

Puc J, Kozbial P, Li W, Tan Y, Liu Z, Suter T, Ohgi KA, Zhang J, Aggarwal AK, Rosenfeld MG.

Cell. 2015 Jan 29;160(3):367-80. doi: 10.1016/j.cell.2014.12.023. Epub 2015 Jan 22. Erratum in: Cell. 2015 Oct 8;163(2):520-2.

7.

NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas.

Asch-Kendrick RJ, Samols MA, Lilo MT, Subhawong AP, Sharma R, Illei PB, Argani P, Cimino-Mathews A.

J Clin Pathol. 2014 Sep;67(9):768-71.

8.

Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.

Sequeiros T, García M, Montes M, Oliván M, Rigau M, Colás E, de Torres I, Morote J, Reventós J, Doll A.

Biomed Res Int. 2013;2013:283635. doi: 10.1155/2013/283635. Epub 2013 Nov 25. Review.

9.

Expression changes in the stroma of prostate cancer predict subsequent relapse.

Jia Z, Rahmatpanah FB, Chen X, Lernhardt W, Wang Y, Xia XQ, Sawyers A, Sutton M, McClelland M, Mercola D.

PLoS One. 2012;7(8):e41371. doi: 10.1371/journal.pone.0041371. Epub 2012 Aug 1. Erratum in: PLoS One. 2012;7(9). doi: 10.1371/annotation/7de63575-e5c9-4f1d-bb45-fc6420e92c71.

10.

Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges.

Dasgupta S, Srinidhi S, Vishwanatha JK.

J Carcinog. 2012;11:4. doi: 10.4103/1477-3163.93001. Epub 2012 Feb 17.

11.

DNA methylation in promoter region as biomarkers in prostate cancer.

Yang M, Park JY.

Methods Mol Biol. 2012;863:67-109. doi: 10.1007/978-1-61779-612-8_5.

12.

Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples.

Gallagher MF, Heffron CC, Laios A, O'Toole SA, Ffrench B, Smyth PC, Flavin RJ, Elbaruni SA, Spillane CD, Martin CM, Sheils OM, O'Leary JJ.

J Ovarian Res. 2012 Jan 19;5(1):2. doi: 10.1186/1757-2215-5-2.

13.

Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.

Tan PY, Chang CW, Chng KR, Wansa KD, Sung WK, Cheung E.

Mol Cell Biol. 2012 Jan;32(2):399-414. doi: 10.1128/MCB.05958-11. Epub 2011 Nov 14.

14.

MYC and Prostate Cancer.

Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM.

Genes Cancer. 2010 Jun;1(6):617-28. doi: 10.1177/1947601910379132.

15.

Molecular genetics of prostate cancer: new prospects for old challenges.

Shen MM, Abate-Shen C.

Genes Dev. 2010 Sep 15;24(18):1967-2000. doi: 10.1101/gad.1965810. Review.

Supplemental Content

Support Center